Expertise in Testing Adoptive Cell Therapies

Companies developing Adoptive Cell Therapies (ACTs), and particularly those with CAR T cell therapies, will discover in MI Bioresearch an unparalleled breadth of experience in the use of mouse tumor models to evaluate ACTs. With a broad range of disseminated and subcutaneous tumor models characterized in NSG mice, and a scientific team that knows how to apply them, we can guide selection of the right tumor model for your CAR T cell or other ACT study.

MI Bioresearch has a “sweet spot” in evaluating hematological malignancy models based on a long-standing heritage in the use of bioluminescence imaging (BLI) to track disseminated tumor burden. With over 80 unique hematological malignancy cell lines, such as the CD19+ Raji-Luc lymphoma model, the MV-411-Luc leukemia model, and the MM.1S-Luc multiple myeloma model, we lead the industry with market-relevant models for your studies. We also have an ever-expanding list of solid tumor models validated in NSG mice to support the field’s drive toward approval of an ACT in a solid tumor indication.

Explore below the range of tumor models and in vitro services that we can apply to your CAR T cell or other ACT study.

Milestones in Adoptive Cell Therapy

The technologies and services at MI Bioresearch have moved in the same direction as the ACT field putting us in a unique position to be poised for supporting CAR T cell and other ACT approaches.

Image of Adoptive Cell Therapy Timeline and Key Milestones for MI Bioresearch

Tumor Models Characterized in NSG Mice

List of Models in NSG Mice (Currently Available)

Model Histotype
22Rv1 Prostrate carcinoma
H-1299 Non-small cell lung carcinoma
Hep 3B2.1-7 Hepatocellular carcinoma
KG-1-Luc-mCh-Puro Myeloid leukemia
MM1.S (pMMP-Luc-Neo) Plasma cell myeloma
MOLM-13 Plasma cell myeloma
MV4-11-FUW-Luc-mCh-Puro Acute monocytic leukemia (AML)
NALM6-Luc-mCh-Puro Lymphoblastic leukemia
NCI-H929-Luc-mCh-Puro Plasma cell myeloma
PC-3 Prostrate carcinoma
Raji-Luc Lymphoma
RPMI-8226 Plasma cell myeloma
SK-MEL-28 Melanoma
SK-OV-3-Luc-D3  &  SK-OV-3 Ovarian adenocarcinoma
SNU-5 Gastric carcinoma
U-251-Luc-mCh-Puro Glioblastoma

List of Models in NSG Mice (In Progress)

Model Histotype
A549 Non small cell lung carcinoma
BT-20 Mammary ductal carcinoma
BT-474 Mammary ductal carcinoma
BxPC-3 Pancreatic adenocarcinoma
H-1299 Non-small cell lung carcinoma
Jurkat Lymphoblastic leukemia
MDA-MB-231-Luc-D3H2LN Mammary carcinoma
NCI-H1703 Squamous cell lung carcinoma
NCI-H1975 Lung adenocarcinoma
SK-BR-3 Mammary adenocarcinoma

Tumor Models by Histotype Being Targeted with Adoptive Cell Therapy:

Hematological malignancies:

Acute Myeloid Leukemia

Leukemia [AML]
EOL-1
Kasumi-3
Kasumi-3-Luc-mCh-Puro
KG-1-Luc-mCh-Puro
MOLM-13
MV-4-11
NOMO-1
Human
C1498
Mouse

B-cell Malignancies

Leukemia [B-ALL]
NALM6
NALM6-Luc-MCh-Puro
Reh
RS4;11
Human
Lymphoma [B-Cell]
DB
DB/M2
Human
Mouse
Lymphoma [B-NHL]
Farage
GRANTA-519
Human
Lymphoma [Burkitt’s]
B-JAB
Daudi
NAMALWA
Raji
Ramos-Luc
Human
Lymphoma [DLBCL]
OCI-Ly1 LN
OCI-Ly19-Luc-Neo
OCI-Ly3-Luc-mCh-Puro
OCI-Ly7-Luc-mCh-Puro (rescued)
OCI-Ly7-Luc-Neo
Pfeiffer
SU-DHL-10-LN-High
SU-DHL-16
SU-DHL-4-Luc-mCh-Puro
SU-DHL-8
TMD8
Toledo-Luc-Neo
WSU-DLCL2
Human

Multiple Myeloma

Myeloma
JJN-3-Luc
NCI-H929
OPM-2
RPMI 8226
U266B1
Human
J558
Mouse

Solid Tumors:

Glioblastoma Multiforme

Brain
BT142
DBTRG (tumor)
DBTRG-05MG
Gli36-DsRed-R-Luc (rescued)
LN-18
LN-229
M059K
SF-295
SF-539
SF-767
SNB-19
U-87 MG
U251
Human
GL261
Mouse

Hepatocellular Carcinoma

Liver
Hep 3B2.1-7
Hep G2
Human
BNL 1ME A.7R.1
BNL 1ME A.7R.1-Luc-mCh-Puro
Hep55.1c
Hepa 1-6-Luc-mCh-Puro
Mouse

Lung

Lung
LL/2-Luc-M38
Mouse
Lung [Adenosquamous]
NCI-H596
Human
Lung [Anaplastic Carcinoma]
Calu-6
Human
Lung [Bronchioalveolar]
NCI-H322M
Human
Lung [NSCLC]
A549-Luc-C8
Calu-1
Calu-3
HCC827
HCC827-Luc-mCh-Puro
NCI-H125
NCI-H125-Luc
NCI-H1299
NCI-H1650
NCI-H1703
NCI-H1703-Luc-mCh-Puro
NCI-H1975-Luc
NCI-H2110
NCI-H2122
NCI-H441
NCI-H460-Luc2
NCI-H522
PC-9
Human
Lung [SCLC]
DMS 114
NCI-H446
NCI-H69
NCI-H82
SHP-77
Human
Lung [Squamous]
EBC-1
SK-MES-1
Human

Mammary/Breast

Mammary/Breast
BT-20
BT-474
Hs 578Bst
Hs 578T
MCF 10A
MCF7-Luc-mCh-Puro
MDA-MB-231-2LMP
MDA-MB-231-Luc-D3H1
MDA-MB-231-Luc-D3H2
MDA-MB-231-Luc-D3H3
MDA-MB-361
MDA-MB-453
MDA-MB-468
MX-1-Luc
SK-BR-3
T47D
Human
MMTV-PyMT
Mouse

Ovarian Cancer

Ovarian
A2780-Luc
IGROV1-Luc-Mch-Puro
NIH:OVCAR-3
NIH:OVCAR-3-Luc-mCh-Puro
OV-90
OVCAR-4
OVCAR-5-Luc-mCh-Puro
OVCAR-8-Luc-mCh-Puro
Human
Mouse

Prostate Cancer

Prostate
22Rv1
CWR-22-R
DU 145-Luc
LnCap clone FGC
PC-3-Luc
PC-3M-Luc-C6
VCaP
Human

See our full list of human and mouse cell lines.

 

Support with In Vitro Services Under the Same Roof for your ACT Studies

  • Flow Cytometry
  • Luminex, Cytometric Bead Array
  • ELISA Assays (custom and off the shelf)
  • Histology and IHC
  • Proliferation assays
  • High content image analysis
  • qPCR/RT-PCR
  • Custom assay development
    • Ex vivo flow cytometry
    • 3D matrix assays
    • Biochemical assays

Click here for details about our In Vitro Services

 

MI Bioresearch is continually improving and expanding its adoptive cell therapy (ACT) capabilities. Keep checking back for updates and learn how we can help you with your next ACT study.